Lahjavida has developed a new proprietary Dye-Drug Conjugate (DDC) delivery platform to empower standard-of-care chemotherapy drugs to target a multitude of cancer tumors, anywhere in the body, while protecting healthy tissues. These novel DDCs overcome current treatment limitations and provide many advantages including: Potential to treat over 30 different cancer-types, Low systemic toxicity, etc.
